Revive Therapeutics Files Business Acquisition Report
February 08, 2021 17:39 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), announces that it has filed a Form 51-102F4 Business Acquisition Report (BAR)...
Revive Therapeutics Included in First Psychedelic Exchange Traded Fund
January 22, 2021 11:05 ET
|
Revive Therapeutics Ltd.
TORONTO, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin
January 14, 2021 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study
December 31, 2020 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access
December 23, 2020 08:55 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program
December 21, 2020 07:59 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor
December 02, 2020 13:11 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for...
Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics
November 18, 2020 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for...
Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin
November 11, 2020 09:10 ET
|
Revive Therapeutics Ltd.
TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
October 26, 2020 09:21 ET
|
Revive Therapeutics Ltd.
TORONTO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...